NASDAQ:GMAB Genmab A/S (GMAB) Stock Price, News & Analysis $37.82 +0.93 (+2.52%) Closing price 04:00 PM EasternExtended Trading$37.82 0.00 (0.00%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Genmab A/S Stock (NASDAQ:GMAB) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Genmab A/S alerts:Sign Up Key Stats Today's Range$37.04▼$38.3350-Day Range$30.85▼$38.4852-Week Range$23.62▼$40.17Volume4.08 million shsAverage Volume4.05 million shsMarket Capitalization$23.60 billionP/E Ratio26.54Dividend YieldN/APrice Target$42.50Consensus RatingModerate Buy Company Overview Genmab A/S is a biotechnology company headquartered in Copenhagen, Denmark, focused on developing differentiated antibody-based medicines for the treatment of cancer and other serious diseases. The company uses proprietary antibody technologies, including its DuoBody and HexaBody platforms, to create therapies designed to engage the immune system, target disease-related proteins and improve treatment outcomes. Genmab’s portfolio includes products developed through partnerships as well as internally discovered candidates. Its technologies have contributed to medicines such as DARZALEX (daratumumab) for multiple myeloma, Kesimpta (ofatumumab) for relapsing forms of multiple sclerosis, and Tivdak (tisotumab vedotin) for certain patients with cervical cancer. Genmab and AbbVie also developed EPKINLY (epcoritamab-bysp), a treatment for certain types of B-cell lymphoma. Commercial rights and responsibilities for these products vary among Genmab and its collaborators. Founded in 1999, Genmab serves international markets through research, development and commercial partnerships spanning North America, Europe and other regions. The company maintains operations in Denmark, the United States and additional locations supporting its global development activities. Genmab is led by Dr. Jan van de Winkel, who serves as President and Chief Executive Officer and has been associated with the company’s scientific and operational development for many years.AI Generated. May Contain Errors. Read More Genmab A/S Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks79th Percentile Overall ScoreGMAB MarketRank™: 3.950601150025 of 5 starsGenmab A/S scored higher than 79% of companies evaluated by MarketBeat, and ranked 130th out of 870 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingModerate Buy Consensus RatingGenmab A/S has received a consensus rating of Moderate Buy. The company's average rating score is 2.85, and is based on 1 strong buy rating, 9 buy ratings, 3 hold ratings, and no sell ratings.Upside PotentialGenmab A/S has a consensus price target of $42.50, representing about 12.4% upside from its current price of $37.82.Amount of Analyst CoverageGenmab A/S has been the subject of 5 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Genmab A/S's stock forecast and price target. Earnings and Valuation3.1 / 5Proj. Earnings Growth33.06% Earnings GrowthEarnings for Genmab A/S are expected to grow by 33.06% in the coming year, from $1.21 to $1.61 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Genmab A/S is 29.78, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 38.85.Price to Earnings Ratio vs. SectorThe P/E ratio of Genmab A/S is 29.78, which means that it is trading at a less expensive P/E ratio than the Healthcare sector average P/E ratio of about 274.96.Price to Earnings Growth RatioGenmab A/S has a PEG Ratio of 1.69. PEG Ratios above 1 indicate that a company could be overvalued.Price to Book Value per Share RatioGenmab A/S has a P/B Ratio of 4.16. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Genmab A/S's valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.99% of the float of Genmab A/S has been sold short.Short Interest Ratio / Days to CoverGenmab A/S has a short interest ratio ("days to cover") of 2.09, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Genmab A/S has recently increased by 23.20%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGenmab A/S does not currently pay a dividend.Dividend GrowthGenmab A/S does not have a long track record of dividend growth. News and Social Media3.3 / 5News Sentiment0.26 News SentimentGenmab A/S has a news sentiment score of 0.26. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 12 news articles for Genmab A/S this week, compared to 6 articles on an average week.Search Interest10 people have searched for GMAB on MarketBeat in the last 30 days. This is an increase of 100% compared to the previous 30 days.MarketBeat Follows6 people have added Genmab A/S to their MarketBeat watchlist in the last 30 days. Company Ownership0.1 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Genmab A/S insiders have not sold or bought any company stock.Percentage Held by Insiders1.54% of the stock of Genmab A/S is held by insiders.Percentage Held by Institutions7.07% of the stock of Genmab A/S is held by institutions.Read more about Genmab A/S's insider trading history. Receive GMAB Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Genmab A/S and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. GMAB Stock News HeadlinesBarclays Sticks to Their Buy Rating for Genmab A/S (0MGB)October 15 at 8:57 AM | theglobeandmail.comGenmab Reports $4.24 Billion In Third-Quarter DARZELEX Sales, Up Year Over YearOctober 13 at 8:56 AM | rttnews.comHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - but now he believes he's found something better. This under-the-radar company sits at the intersection of America's two most important industries, including AI, pays massive dividends, and attracted a famous money manager who put 60% of his multi-billion-dollar fund into it. Tilson is revealing the name and ticker symbol completely free - no credit card or email required.October 15 at 1:00 AM | Stansberry Research (Ad)Genmab Reports $4.24 Billion in Q3 DARZALEX Sales, Earns Royalties From J&JOctober 13 at 8:56 AM | finance.yahoo.comGenmab Announces Net Sales of DARZALEX® (daratumumab) for Third Quarter of 2026October 13 at 6:22 AM | globenewswire.comHC Wainwright Analysts Cut Earnings Estimates for Genmab A/SOctober 11, 2026 | americanbankingnews.comGenmab A/S Stock Earnings Estimates Lifted by HC WainwrightOctober 10, 2026 | americanbankingnews.comGenmab To Issue Restricted Stock Units To Board Members As RenumerationOctober 7, 2026 | rttnews.comSee More Headlines GMAB Stock Analysis - Frequently Asked Questions How have GMAB shares performed this year? Genmab A/S's stock was trading at $30.80 at the beginning of the year. Since then, GMAB stock has increased by 22.8% and is now trading at $37.82. How were Genmab A/S's earnings last quarter? Genmab A/S Sponsored ADR (NASDAQ:GMAB) released its earnings results on Thursday, August, 6th. The company reported $0.54 EPS for the quarter, topping analysts' consensus estimates of $0.37 by $0.17. The firm earned $1.16 billion during the quarter, compared to analysts' expectations of $1.12 billion. Genmab A/S had a net margin of 19.08% and a trailing twelve-month return on equity of 14.89%. Read the conference call transcript. When did Genmab A/S IPO? Genmab A/S (GMAB) raised $503 million in an initial public offering (IPO) on Thursday, July 18th 2019. The company issued 27,800,000 shares at a price of $18.11 per share. BofA Merrill Lynch, Morgan Stanley and Jefferies acted as the underwriters for the IPO and Guggenheim Securities and RBC Capital Markets were co-managers. Who are Genmab A/S's major shareholders? Top institutional shareholders of Genmab A/S include Perpetual Ltd (0.12%), Legacy Wealth Asset Management LLC (0.02%), Terra Nova Asset Management LLC (0.01%) and Versant Capital Management Inc. How do I buy shares of Genmab A/S? Shares of GMAB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Genmab A/S own? Based on aggregate information from My MarketBeat watchlists, some other companies that Genmab A/S investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Marvell Technology (MRVL), PayPal (PYPL), Fortinet (FTNT), Alibaba Group (BABA) and Bristol Myers Squibb (BMY). Company Calendar Last Earnings8/06/2026Today10/15/2026Next Earnings (Estimated)11/05/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (2m+) 1-Year History Oct 25 Jan 26 Apr 26 Jul 26 Oct 26 GMAB's financial health is in the Green zone, according to TradeSmith. GMAB has been in this zone for over 2 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolNASDAQ:GMAB CIK1434265 Webwww.genmab.com Phone(457) 020-2728FaxN/AEmployees3,029Year Founded1999Price Target and Rating Average Price Target for Genmab A/S$42.50 High Price Target$54.00 Low Price Target$32.00 Potential Upside/Downside+12.4%Consensus RatingModerate Buy Rating Score (0-4)2.85 Research Coverage13 Analysts Profitability EPS (Trailing Twelve Months)$1.27 Trailing P/E Ratio26.54 Forward P/E Ratio31.52 P/E Growth1.72Net Income$963 million Net Margins19.08% Pretax Margin21.93% Return on Equity14.89% Return on Assets7.73% Debt Debt-to-Equity Ratio0.81 Current Ratio2.46 Quick Ratio2.44 Sales & Book Value Annual Sales$3.72 billion Price / Sales6.34 Cash Flow$1.65 per share Price / Cash Flow22.92 Book Value$9.10 per share Price / Book4.16Miscellaneous Outstanding Shares624,060,000Free Float614,448,000Market Cap$23.60 billion OptionableOptionable Beta0.81 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:GMAB) was last updated on 10/15/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredTrump's New DollarPorter Stansberry says President Trump has signed an executive order initiating what he calls a full U.S. doll...Porter & Company | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredThe end may be near for these iconic stocksMarc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...Chaikin Analytics | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Genmab A/S Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Genmab A/S With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
